2,4-thiazolidinedione has been researched along with Neoplasms in 12 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While there was evidence that type 2 diabetes is associated with an increased risk of cancer, existing studies seemed insufficient to definitively demonstrate a link between cancer risk and use of specific anti-hyperglycemic therapies." | 2.55 | Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal. ( Kosiborod, M; Leiter, LA; Poulter, NR; Rajagopalan, S; Ray, K; Vora, J, 2017) |
| "The anticancer activity of novel thiazolidine-2,4-diones was evaluated against HepG2, HCT-116, and MCF-7 cells." | 1.62 | Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. ( Abulkhair, HS; El-Adl, K; El-Hddad, SSA; El-Helby, AA; Nasser, M; Sakr, H, 2021) |
| "Hyperglycemia is associated with increased risk of all-site cancer that may be mediated through activation of the renin-angiotensin-system (RAS) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A-reductase (HMGCR) pathways." | 1.40 | Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes. ( Chan, JC; Cheung, KK; Chow, CC; Kong, AP; Lee, HM; Luk, A; Ma, RC; Ozaki, R; So, WY; Xu, G; Yang, X; Yu, L, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, VS | 1 |
| Vora, DK | 1 |
| Ramaa, CS | 1 |
| Ruggiero, D | 1 |
| Terracciano, S | 1 |
| Lauro, G | 1 |
| Pecoraro, M | 1 |
| Franceschelli, S | 1 |
| Bifulco, G | 1 |
| Bruno, I | 1 |
| Vora, J | 1 |
| Ray, K | 1 |
| Kosiborod, M | 1 |
| Poulter, NR | 1 |
| Rajagopalan, S | 1 |
| Leiter, LA | 1 |
| Kong, AP | 1 |
| Yang, X | 1 |
| So, WY | 1 |
| Luk, A | 1 |
| Ma, RC | 1 |
| Ozaki, R | 1 |
| Cheung, KK | 1 |
| Lee, HM | 1 |
| Yu, L | 1 |
| Xu, G | 1 |
| Chow, CC | 1 |
| Chan, JC | 1 |
| Tontonoz, P | 1 |
| Spiegelman, BM | 1 |
| Xia, Z | 1 |
| Knaak, C | 1 |
| Ma, J | 1 |
| Beharry, ZM | 1 |
| McInnes, C | 1 |
| Wang, W | 1 |
| Kraft, AS | 1 |
| Smith, CD | 1 |
| Omar, HA | 1 |
| Berman-Booty, L | 1 |
| Weng, JR | 1 |
| Scatena, R | 1 |
| Martorana, GE | 1 |
| Bottoni, P | 1 |
| Giardina, B | 1 |
| Tomita, K | 1 |
| Hanafusa, T | 1 |
| Roberts-Thomson, SJ | 1 |
| Murphy, GJ | 1 |
| Holder, JC | 1 |
| El-Adl, K | 1 |
| Sakr, H | 1 |
| El-Hddad, SSA | 1 |
| El-Helby, AA | 1 |
| Nasser, M | 1 |
| Abulkhair, HS | 1 |
8 reviews available for 2,4-thiazolidinedione and Neoplasms
| Article | Year |
|---|---|
Thiazolidine-2,4-diones: progress towards multifarious applications.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumato | 2013 |
Cancer risks of anti-hyperglycemic drugs for type 2 diabetes treatment - a clinical appraisal.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Incretins; Insulin | 2017 |
Fat and beyond: the diverse biology of PPARgamma.
Topics: Adipocytes; Adipogenesis; Animals; Cell Nucleus; Humans; Inflammation; Insulin Resistance; Macrophag | 2008 |
Energy restriction: stepping stones towards cancer therapy.
Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Energy Metabolism; Enzyme Inhibitors; H | 2012 |
Mitochondrial dysfunction by synthetic ligands of peroxisome proliferator activated receptors (PPARs).
Topics: Animals; Humans; Hypoglycemic Agents; Ligands; Lipid Metabolism; Liver; Mitochondria; Mitochondrial | 2004 |
[PPARs, cancer cells and inflammation].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Differentiation; Cytokines; Humans; Inflammat | 2000 |
Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment.
Topics: Animals; Cell Cycle; Cell Differentiation; Colonic Neoplasms; Humans; Lipid Metabolism; Liver Neopla | 2000 |
PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
Topics: Animals; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Inflammation; Ligands; Neoplasms; | 2000 |
4 other studies available for 2,4-thiazolidinedione and Neoplasms
| Article | Year |
|---|---|
Structural Refinement of 2,4-Thiazolidinedione Derivatives as New Anticancer Agents Able to Modulate the BAG3 Protein.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Protein | 2022 |
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose; Hemoglobin A; Humans; Hydroxymethylglutar | 2014 |
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell-Free System; Combinatorial Chemistry Techniques; Fem | 2009 |
Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; HCT116 Cells; Hep G2 Cells; Hu | 2021 |